CHARLESTON, S.C., Jan. 19, 2011 (GLOBE NEWSWIRE) -- Revolutions Medical ("Revolutions Medical" or the "Company") (OTCBB:RMCP) has received notice that Investigational Review Board (IRB) approval has been granted to Dr. Yong Wei, Assistant Professor of Computer Science at North Georgia College and State University (NGCSU) and Dr. H. Keith Brown, Professor of Anatomy at the Philadelphia College of Osteopathic Medicine (PCOM-GA) for their clinical study 'Statistical Analysis of Abdomen Tissue Segmentation by Color Fusion MRI.' This first collaboration will be to work on the establishment of statistical confidence levels associated with automatic tissue segmentation using the Revolutions Medical's proprietary MRI software tools: RevColor, Rev3D and RevDisplay. In this research study, automatic MRI Image segmentation will be evaluated for clinical applications that may help to locate tumors and other pathologies, measure tissue volumes, plan computer-guided surgery and treatments and provide improved visualization of anatomical structures.
Tom O'Brien, President of Revolutions Medical, states, "This is the first IRB approval for a clinical study to be done on the abdomen utilizing our proprietary MRI software tools. We believe that this study will lead the way for the validation of a number of different applications for the body. I am excited that Drs. Keith Brown, Yong Wei and their colleagues have followed up with this new IRB approved study after having been granted IRBs for work being done in the brain. Now that we are fully underway with an ever growing list of studies validating possible applications utilizing our MRI software platform, I am confident that we will soon have a body of work to present to possible MRI luminaries and possible licensing partners as we get closer to offering these products for sale."
The interview is available at , or directly via the link provided below:
About Revolutions Medical Corporation
Revolutions Medical is a safety medical device and software application company. Its products include the RevVac Safety Syringe (FDA approved), safety blood drawing device; and the RevColorTM, RevDisplayTM and Rev3DTM software tools that are compatible with standard MRIs and standard Picture Archiving Computer Systems (PACS). The Company also has an exclusive license to a Breast Biopsy System (BBS) preliminary called RevTrack (FDA approved).
For additional information, please visit Revolutions Medical corporate website:
To be added to the Revolutions Medical investor email list, please email with RMCP in the subject line.
Become a RevMed fan and follow the Company on Facebook -- visit http://www.Facebook.com/Revmed
The information contained herein includes forward-looking statements. These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. The safe harbor for forward-looking statements contained in the Securities Litigation Reform Act of 1995 protects companies from liability for their forward-looking statements if they comply with the requirements of the Act.
CONTACT: Revolutions Medical Corporation Investor Relations: Scott Key (843) 518-0437 Skey@revolutionsmedical.com